• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1.5 Contact Hour(s)

    Release Date

    Monday, September 16, 2019

    Offline Date

    Wednesday, September 16, 2020

    ACPE Expiration Date

    Tuesday, July 12, 2022

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      Cardiovascular disease (CVD) remains the leading cause of death in the United States. The American Heart Association estimates that 33% of men aged 40 to 59 and nearly 33% of women aged 60 years and older have high triglyceride levels. Most goals for CVD prevention or management involve raising HDL levels while lowering LDL and triglyceride levels to recommended ranges. However, more and more research is showing that triglyceride levels are an independent risk factor for CVD, greatly increasing the chances of heart disease and stroke. This activity will offer pharmacists a greater understanding of the new cholesterol guidelines and review CV outcomes trials to improve management of patients at risk of ASCVD events. 

      Indepth review of ASCVD cardiovascular trials - printed slides maybe useful if using a phone or small screen.

      Handouts

      • Slide Document :   19133H01_6pp.pdf
      • Slide Document :   19133H01_2pp.pdf

      Financial Support By

      Amarin Pharma Inc
    • Pharmacist

      Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
      Describe the spectrum of major recent ASCVD randomized cardiovascular outcomes trials
      Apply evidence-based guidelines, recent randomized clinical trial evidence, and cost implications to therapeutic approaches for managing patients at high risk of cardiovascular events
      Have greater clarity on implementing the new 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol

      Nurse

      Apply evidence-based guidelines, recent randomized clinical trial evidence, and cost implications to therapeutic approaches for managing patients at high risk of cardiovascular events
      Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
      Have greater clarity on implementing the new 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol
      Describe the spectrum of major recent ASCVD randomized cardiovascular outcomes trials
    • Activity Type

      Knowledge

      CE Broker

      20-739160

      Universal Activity Number

      Pharmacist 0798-0000-19-133-H01-P
      Nurse 0798-0000-19-133-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).